Global Medical Cyclotron Market Overview:
Medical Cyclotron is an electrical machine that produces mainly positron emitters, to be used for medical diagnostics or therapies in nuclear medicine. In a medical cyclotron, particles such as protons, deuterons are faster and made to attack a suitable target material to produce positron-emitting radioisotopes. The medical cyclotrons are mainly classified as self-shielded or non-self-shielded ones. The self-shielded medical cyclotrons are incorporated with heavy shielding around the cyclotron. Additional structural shielding needs to be delivered for non-self-shielded medical cyclotron to diminish the radiation levels to within safe limits.
Attributes | Details |
---|
Study Period | 2017-2027 |
Base Year | 2021 |
Forecast Period | 2022-2027 |
Historical Period | 2017-2021 |
Unit | Value (USD Million) |
Customization Scope | Avail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility |
Influencing Trend:
Growing Availability of Cyclotrons, to Produce Radioisotopes
Market Growth Drivers:
Rising Need for Diagnosis and Treatment of Neurological Diseases and Increasing Acceptance for PET Medical Accelerators
Challenges:
High Competition from Established Players
Restraints:
High Price of Medical Cyclotron
Opportunities:
Increasing Demand for Nuclear Scans and Advancement in Medical Imaging Technology
Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers competing. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.
Some of the key players profiled in the report are Ion Beam Applications SA (Belgium), GE Healthcare (United States), Siemens Healthineers (Germany), Advanced Cyclotron Systems (Canada), Sumitomo Heavy Industries, Ltd. (Japan), Best Cyclotron Systems, Inc. (Canada), Ionetix (United States), Varian Medical Systems, Inc. (United States), Isosolution Inc. (Canada), Alcen (France) and TeamBest (United States). Analyst at AMA Research see North America Players to retain maximum share of Global Medical Cyclotron market by 2027. Considering Market by End-Users, the sub-segment i.e. Hospitals will boost the Medical Cyclotron market.
Latest Market Insights:
In October 2022, IBA Radiopharma Solutions partnered with Novatec International and ElsMed Healthcare Solutions for an integrated radiopharmaceutical production facility in Tbilisi, Georgia.
On March 11, 2024, Actinium Pharmaceuticals, Inc. launched a strategic initiative focused on the manufacture of the medical isotope Actinium-225 (Ac-225) using proprietary cyclotron-based technology.
To establish a Medical Cyclotron facility, the user institute must go through the Regulatory requirements as mentioned in the Atomic Energy (Radiation Protection) Rules, 2004 and AERB Safety Guide on Medical Cyclotron facilities and shall obtain requisite regulatory consent from AERB as per AERB Safety Guide for Consenting process for Radiation Facilities (AERB/SG/G-3).
What Can be Explored with the Medical Cyclotron Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Medical Cyclotron Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Medical Cyclotron
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Medical Cyclotron market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Medical Cyclotron market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Medical Cyclotron, Suppliers of Medical Cyclotron, Wholesalers, Distributors and Retailers of Medical Cyclotron, Healthcare Industry, Regulatory Bodies and Governmental Bodies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.